期刊文献+

基于治未病与治已病的临床需求创新中成药的发展 被引量:19

Innovative Chinese Patent Medicine Based on the Clinical Needs of Preventive Treatment Diseases and Treatment Diseases
在线阅读 下载PDF
导出
摘要 创新发展中成药对于满足人们的健康需求,推动我国医药经济发展具有重要价值。中成药的创新发展既要有药的理论指导,符合现代药剂的基本要求,成分清晰,质量稳定,功效明确,朝着数字化、标准化、现代化的方向发展;同时也要有中医的理论指导,体现中医思维,立足中医的比较优势,满足临床需求。中医的临床需求可以分为治未病和治已病两个方面。在治未病方面,可以调体质以改善亚健康,调治慢病防传变,以及扶正祛邪防时疫;在治已病方面,重点可以放在攻克身心疾病、急危重症和细菌耐药方面。 Innovative development of proprietary Chinese medicines is of great value in meeting people’s health needs and promoting the development of China’s pharmaceutical economy.The innovative development of proprietary Chinese medicines must not only have the theoretical guidance of medicines,but also meet the basic requirements of modern pharmaceuticals.The composition is clear,the quality is stable,the efficacy is clear,and it is developing in the direction of digitization,standardization and modernization.At the same time,there must be theoretical guidance from Chinese medicine.TCM thinking,based on the comparative advantages of Chinese medicine,to meet clinical needs.The clinical needs of Chinese medicine can be divided into two aspects:treating the disease and treating the disease.In the treatment of untreated diseases,physical fitness can be adjusted to improve sub-health,to regulate chronic diseases and prevent mutations,and to protect the epidemic from stagnation and evil spirits;in the treatment of existing diseases,the focus can be on conquering psychosomatic diseases,critical illness and bacterial resistance.
作者 章程鹏 吕文亮 刘大会 许鹏 ZHANG Cheng-peng;LYU Wen-liang;LIU Da-hui;XU Peng(Clinical CollegE-of TCM,Hubei University of Traditional ChinesE-Medicine,Wuhan,430061,China)
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2020年第1期116-118,共3页 Journal of Nanjing University of Traditional Chinese Medicine
基金 中国工程院院地合作项目(5)
关键词 中成药 治未病 治已病 创新发展 Chinese patent medicine preventive treatment of disease treatment of disease innovation and development
作者简介 第一作者:章程鹏,男,副教授,E-mail:whzcp0531@163.com;通信作者:吕文亮,男,教授,博士生导师,主要从事中医疫病理论防治重大感染性疾病的研究,E-mail:lvwenliang66@126.com。
  • 相关文献

参考文献2

二级参考文献21

  • 1罗国安,王义明,梁琼麟,等.中医药系统生物学[M].北京:科学出版社,2011:1-5.
  • 2宋民宪,郭维加.新编国家中成药[J].北京:人民卫生出版社.2002.
  • 3WANG Y, LIU L, HU C C, et al. Effects of Salviae Mitiorrhizae and Cortex Moutan extract on the rat heart after myocardial infarc- tion : a proteomic study [ J ]. Biochem Pharmacol, 2007, 74 ( 3 ) :415.
  • 4WU L H, WANG Y, NIE J, et al. A network pharmacology ap- proach to evaluating the efficacy of Chinese medicine using ge- nome-wide transcriptional expression data [ J ]. Evid Based Com- plement Alternat Med, 2013, 2013 : 915343.
  • 5WANG L L, LI Z, ZHAO X P, et al. A network dtudy of Chi- nese medicine Xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway [ J ]. Evid Based Complement Alternat Med, 2013, 2013 : 652373.
  • 6JIN Y C, ZHAO X P, ZHANG Y F, et al. A three-stage-integra- tive approach for the identification of potential hepatotoxic com- pounds from botanical products [J]. Int J Toxicol, 2011,30 (3) : 287.
  • 7ZHANG Y F, SHIP Y, YAO H, et al. Metabolite profiling and pharmacokiuetics of herbal compounds following oral administra-tion of a cardiovascular multi-herb medicine ( Qishen Yiqi pills) in rat[J]. Curr Drug Metab, 2012, 13(5) : 510.
  • 8FAN X H, WANG Y, CHENG Y Y. LC/MS fingerprinting of Shenmai injection: a novel approach to quality control of herbal medicines[J]. J Pharm Biomed Anal, 2006, 40(3) : 591.
  • 9HUANG H X, QU H B. In-line monitoring of alcohol precipitati- on by near-infrared spectroscopy in conjunction with multivariate batch modeling[ J]. Anal Chim Acta, 2011, 707 (1) : 47.
  • 10Xu J, Lian F, Zhao L, et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chi- nese herbal formula [J]. ISME J, 2015,9(3):552-562.

共引文献263

同被引文献243

引证文献19

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部